Peptide LibraryDasiglucagon
Also known as: Zegalogue, ZP4207
Dasiglucagon (also called Zegalogue or ZP4207) is an FDA-approved glucagon analog for severe hypoglycemia. Dasiglucagon is a glucagon receptor agonist. It activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood, so it works only if the liver has glycogen to release.
For research use only.
Key Facts
- CAS
- 1544300-84-6
- Molecular Weight (MW)
- 3382 g/mol
- Half-life
- About 30 minutes
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Single dose for an emergency, not a scheduled medicine
- Last updated
- Oct 30, 2026
- Reviewed
- Oct 30, 2026
- Targets
- Glucagon receptor
Research summary
FDA-approved glucagon analog (Zegalogue) for severe hypoglycemia in people with diabetes who weigh at least 20 kg. A ready-to-use rescue injection; Drugs@FDA lists both presentations as discontinued.
Research evidence
- Regulatory review (FDA label)1 reviewed source
- Controlled human trials8 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Dasiglucagon profile summarises 6 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Dasiglucagon dosage evidence
Dasiglucagon has an FDA-approved human dose for emergency use only. As Zegalogue it is a single 0.6 mg subcutaneous injection for severe hypoglycemia in adults and children with diabetes who weigh at least 20 kg, with a second 0.6 mg dose from a new device if there is no response after 15 minutes. FDA's Drugs@FDA database lists both presentations as discontinued, though the approval still stands. Every other dose on this page is research.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.6 mg as a single rescue dose; a second 0.6 mg after 15 minutes if there is no response |
| Route | Subcutaneous |
| Frequency | Single dose for an emergency, not a scheduled medicine |
| Duration studied | Single use |
| Titration | None. The labeled dose is the same for adults and for children who weigh at least 20 kg. |
| Half-life | About 30 minutes |
| Evidence level | FDA Approved |
| Last reviewed | 2026-10-30 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Zegalogue (revised June 2026)FDA-approved label · FDA prescribing information | Adults and children with diabetes who weigh at least 20 kg, for severe hypoglycemia | 0.6 mg; a second 0.6 mg after 15 minutes if there is no response | Subcutaneous, by autoinjector or prefilled syringe | Single rescue dose | — | Rapid rise in blood glucose | ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, revised 06/2026 (Drugs@FDA) |
| Pieber et al., 2021 — phase 3, adults (label Trial A)Clinical trial · Randomised, double-blind phase 3 | Adults with type 1 diabetes during controlled insulin-induced hypoglycemia (n=170) | 0.6 mg, versus placebo or 1 mg of reconstituted glucagon | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 40 on placebo and 12 with glucagon | Pieber TR et al. Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial. Diabetes Care. 2021. |
| Bailey et al., 2021 — phase 3, autoinjector (label Trial B)Clinical trial · Randomised, double-blind phase 3 | Adults with type 1 diabetes during controlled hypoglycemia (n=45) | 0.6 mg by autoinjector, versus placebo | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 35 on placebo | Bailey TS et al. Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial. Diabetes Obes Metab. 2021. |
| Battelino et al., 2021 — phase 3, children (label Trial C)Clinical trial · Randomised, double-blind phase 3 | Children and adolescents aged 6 to 17 with type 1 diabetes (n=42) | 0.6 mg, versus placebo or glucagon dosed per its label | Subcutaneous | Single dose | — | Median time to glucose recovery was 10 minutes versus 30 on placebo and 10 with glucagon | Battelino T et al. Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial. Pediatr Diabetes. 2021. |
| NCT05378672 — phase 3, children under 6 (label Trial D)Clinical trial · Open-label phase 3 with posted results | Children under 6 years, above 8 kg, with type 1 diabetes (n=8) | 0.3 or 0.6 mg, one dose by prefilled syringe into the buttocks | Subcutaneous | — | — | Supported the June 2026 change to a 20 kg weight limit; results posted on the registry | NCT05378672 — A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D |
| Hövelmann et al., 2018 — dose comparisonClinical trial · Randomised, double-blind pharmacokinetic and pharmacodynamic trial | Adults with type 1 diabetes during insulin-induced hypoglycemia (n=58) | 0.1, 0.3, 0.6 or 1.0 mg, versus 0.5 or 1.0 mg of glucagon | Subcutaneous | Single dose | — | Peak level at about 35 minutes and half-life of about 0.5 hours; early glucose response similar to glucagon | Hövelmann U et al. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog. Diabetes Care. 2018. |
| Laugesen et al., 2023 — low-dose pen, phase 2 (not an approved use)Clinical trial · Randomised, open-label crossover phase 2 | Adults with insulin pump-treated type 1 diabetes (n=24) | 80 mcg | Subcutaneous, by pen | As needed for impending or mild hypoglycemia | 2 weeks | Faster recovery and 11% less daily carbohydrate intake than usual care | Laugesen C et al. Pen-administered low-dose dasiglucagon vs usual care for prevention and treatment of non-severe hypoglycaemia in people with type 1 diabetes during free-living conditions: a Phase II, randomised, open-label, two-period crossover trial. Diabetologia. 2023. |
| Nielsen et al., 2023 — hypoglycemia after gastric bypass (not an approved use)Clinical trial · Randomised, double-blind, placebo-controlled crossover trial | People with hypoglycemia after Roux-en-Y gastric bypass (n=24) | 120 mcg | Subcutaneous self-injection | As needed | 4 weeks | Time in level 1 hypoglycemia fell 33% and in level 2 fell 54% versus placebo | Nielsen CK et al. Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2023. |
| Thornton et al., 2024 — congenital hyperinsulinism, phase 3 (not an approved use)Clinical trial · Open-label, randomised phase 3 | Children aged 0.6 to 10.9 years with congenital hyperinsulinism (n=32) | 10 to 70 mcg per hour | Continuous subcutaneous infusion | — | 4 weeks randomized, then 4 weeks in all patients | No significant difference on the primary endpoint; post hoc, 43% less hypoglycemia on continuous glucose monitoring | Thornton PS et al. Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children. J Clin Endocrinol Metab. 2024. |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Preclinical — animal reproduction studiesPreclinical · Animal toxicology reported in the FDA label | Pregnant rats and rabbits | 2, 10 or 24 mg/kg/day in rats and 0.1, 0.3 or 1 mg/kg/day in rabbits; not convertible to a human dose | Subcutaneous | Daily during organogenesis | — | Maternal toxicity, lower fetal weight and delayed bone formation at the higher doses; fetal malformations in rabbits at 0.3 mg/kg/day and above | ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, section 8.1 (Drugs@FDA) |
Where sources disagree
- Dasiglucagon is not glucagon. It is a 29-amino-acid analog with seven substitutions that keep it stable in solution, so glucagon doses and dasiglucagon doses are not interchangeable: 0.6 mg of one was compared with 1 mg of the other.
- FDA's Drugs@FDA database lists both Zegalogue presentations as discontinued, and FDA's NDC directory gives them a marketing end date of 31 August 2027, even though FDA approved a label change in June 2026. Approval and availability are separate questions.
- The June 2026 label covers people who weigh at least 20 kg. DailyMed's copy still showed the older "aged 6 years and above" wording at this review.
- Everything below 0.6 mg, and all continuous infusion, is research. The congenital hyperinsulinism and low-dose uses are not on the label.
- In a low-dose study, nausea and vomiting were more frequent than with the same doses of commercial glucagon, which the authors thought might reflect higher potency.
Handling & administration
- Reconstitution Guide
- No reconstitution: supplied ready to use in an autoinjector or prefilled syringe
- Injection Sites
- Lower abdomenButtocksThighOuter upper arm
Sequence & molecular data
| Amino acid sequence | His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ala-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr |
|---|---|
| Molecular formula | C152H222N38O50 |
| Molecular weight | 3382 g/mol |
| CAS number | 1544300-84-6 |
| Half-life | About 30 minutes |
| Appearance | Clear, colorless solution in a single-dose autoinjector or prefilled syringe |
| Formulation | Solution |
| PubChem CID | 126961379 |
| FDA UNII | AD4J2O47FQ |
| ChEMBL | CHEMBL4297741 |
| DrugBank | DB15226 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Dasiglucagon is a glucagon receptor agonist. It activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood, so it works only if the liver has glycogen to release. It has 29 amino acids like glucagon, with seven substitutions that keep it stable in a ready-to-use solution, whereas glucagon emergency kits use a powder that has to be reconstituted.
Origin
Synthetic glucagon analog developed by Zealand Pharma as ZP4207.
Targets
Studies
- Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
- Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device: Results of a phase 3, randomized, double-blind trial
- Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial
- Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog
- Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children
- Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial
Research statistics
43 PubMed publications · 38.1% human clinical research · 24 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Dasiglucagon is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Discontinued |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
Dasiglucagon side effects
The effects below are drawn from Dasiglucagon's prescribing information, which lists the full adverse-reaction data.
Side Effects
- Nausea (57% of adults, 65% of children)
- Vomiting (25% of adults, 50% of children)
- Headache (11% of adults, 10% of children)
- Diarrhea (5% of adults)
- Injection site pain (2% of adults, 5% of children)
Contraindications
- Pheochromocytoma
- Insulinoma
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Dasiglucagon: frequently asked questions
What is dasiglucagon?
Dasiglucagon is a rescue medicine for severe low blood sugar, sold as Zegalogue. It is a synthetic 29-amino-acid analog of glucagon, supplied as a ready-to-use injection, so there is no powder to mix during an emergency.
How does dasiglucagon work?
Dasiglucagon activates glucagon receptors in the liver, which breaks down stored glycogen and releases glucose into the blood. It needs glycogen to work, so it may fail in starvation, adrenal insufficiency or chronic hypoglycemia.
Is dasiglucagon FDA approved?
Yes. FDA approved Zegalogue on 22 March 2021 (NDA 214231). A June 2026 supplement changed the pediatric limit to children who weigh at least 20 kg. FDA’s Drugs@FDA database now lists both presentations as discontinued, though the approval has not been withdrawn.
Is Zegalogue still available?
FDA’s Drugs@FDA database lists both Zegalogue presentations as discontinued, and FDA’s NDC directory shows a marketing end date of 31 August 2027 for Novo Nordisk’s listings. Check with a pharmacy for current supply, because these databases do not show stock.
What is the labeled dose of dasiglucagon?
The FDA label gives 0.6 mg by subcutaneous injection for adults and children who weigh at least 20 kg. If there is no response after 15 minutes, a second 0.6 mg dose from a new device may be given while waiting for emergency help. This is reference information, not medical advice.
What are the side effects of dasiglucagon?
Nausea and vomiting are the most common: in adults, 57% and 25%, and in children aged 6 to 17, 65% and 50%. Headache and injection site pain also occurred. The label contraindicates it in pheochromocytoma and insulinoma. This is reference information, not medical advice.
What is the half-life of dasiglucagon?
The label gives a half-life of about 30 minutes, with peak plasma levels around 35 minutes after a 0.6 mg dose. It is cleared by proteolytic breakdown in blood, liver and kidney, like native glucagon.
Is dasiglucagon the same as glucagon?
No. It is an analog with seven amino acid substitutions that keep it stable in solution. In the adult phase 3 trial, median recovery was 10 minutes versus 12 with 1 mg of reconstituted glucagon, with no formal comparison, and the doses are not interchangeable.
What compounds are similar to dasiglucagon?
Glucagon is the natural hormone it is based on. Pramlintide and liraglutide are listed alongside it as other diabetes-related peptides, but they act on different receptors and are not rescue medicines.
References
- ZEGALOGUE (dasiglucagon) injection — FDA prescribing information, revised 06/2026External reference
- NDA 214231/S-004 supplement approval letter — FDA, June 2026External reference
- ZEGALOGUE (dasiglucagon) injection — DailyMedExternal reference
- Drugs@FDA — NDA 214231External reference
- Dasiglucagon-A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia — Diabetes Care, 2021External reference
- Dasiglucagon, a next-generation glucagon analogue, for treatment of severe hypoglycaemia via an autoinjector device — Diabetes Obes Metab, 2021External reference
- Dasiglucagon, a next-generation ready-to-use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes — Pediatr Diabetes, 2021External reference
- Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog — Diabetes Care, 2018External reference
- Dasiglucagon for the Treatment of Congenital Hyperinsulinism: A Randomized Phase 3 Trial in Infants and Children — J Clin Endocrinol Metab, 2024External reference
- Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass — Diabetes Care, 2023External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Oct 30, 2026 · Updated Oct 30, 2026 · Version 1
This Dasiglucagon profile is compiled from published literature (6 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Dasiglucagon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →